This site uses cookies to bring you the best experience. Find out more
Skip to main content
↑

News

Find Out The Latest

Keep in touch with exciting developments from The Oxford Science Park and its occupiers here.

Contact us on comms@oxfordsp.com if you would like to know more about any of these stories.

You can also follow us on LinkedIn  

Acquisition of Hinshelwood Building to provide additional space at TOSP

Acquisition of Hinshelwood Building to provide additional space at TOSP

23 Jan 2023

Acquisition of Hinshelwood Building to provide additional space at TOSP Oxford, UK, January 23 2023 –The Oxford Science Park (TOSP), one of Europe's leading locations for science and technology companies, has further expanded its capacity to accommodate innovative firms with the acquisition of the Hinshelwood Building. The 31,581 sq ft building is situated at the centre of the Park. The transaction is part of The Oxford Science Park’s... Read more

Orbit Discovery and SanegeneBio collaborate to identify targeting peptides for RNAi drugs

Orbit Discovery and SanegeneBio collaborate to identify targeting peptides for RNAi drugs

05 Jan 2023

Oxford, UK, 05 January 2023: Orbit Discovery Limited (Orbit), a leader in the discovery of therapeutic peptide hits, today announced it has entered into a Master Service Agreement with SanegeneBio Inc., (Sanegene), a start-up company dedicated to developing novel RNAi-based medicines. The focus of the collaboration is to identify tissue-specific delivery of a wide range of RNA therapeutics to efficiently knock down disease-causing genes. The... Read more

Celleron Therapeutics and Argonaut Therapeutics Announce Completion of Merger to Form IngenOx Therapeutics

Celleron Therapeutics and Argonaut Therapeutics Announce Completion of Merger to Form IngenOx Therapeutics

05 Jan 2023

Oxford, UK – 5 January 2023 Celleron Therapeutics and Argonaut Therapeutics have jointly announced today the completion of a merger agreement to form IngenOx Therapeutics (www.ingenox.com). Supported by Oxford Science Enterprises (OSE), the merger of the two University of Oxford spinout companies brings together drug discovery and clinical development capabilities, which streamlines the R&D process and ensures pipeline... Read more

OrganOx appoints John Liddicoat M.D. as Non-Executive Director to the Board

OrganOx appoints John Liddicoat M.D. as Non-Executive Director to the Board

01 Dec 2022

OrganOx, a world leader in normothermic machine perfusion (NMP), today announces the appointment of Dr. John Liddicoat M.D. as Non-Executive Director to the Board. "I am delighted to be joining OrganOx in the wake of FDA approval. This Company is at the start of its commercial journey in the US and based on my experience of ground breaking medical devices, I can see tremendous potential for this technology to transform the liver transplant... Read more

Exscientia and MD Anderson Launch Strategic Collaboration to Leverage AI in Developing Novel Oncology Treatments

Exscientia and MD Anderson Launch Strategic Collaboration to Leverage AI in Developing Novel Oncology Treatments

14 Nov 2022

Effort aligns MD Anderson’s drug development expertise with Exscientia’s AI-driven patient-first precision medicine and drug discovery platforms OXFORD, England & HOUSTON, Texas--(BUSINESS WIRE)-- Exscientia plc (Nasdaq: EXAI) and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to align the patient-centric artificial intelligence (AI) capabilities of Exscientia with the drug discovery and... Read more

The Daubeny Project

Imaginative design, inspiring spaces.

450,000 sq ft of
premium lab space
completing 2026

Discover More